POM-V Prescription Required Companion Animal

Meloxaid 5 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Meloxicam

Form

Injection

Species

Cats Dogs

Manufacturer

EU Pharmaceuticals Ltd

VMD MA No.

39787/5023

What it's used for

Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation followin...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Meloxaid 5 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal
disorders. Reduction of post-operative pain and inflammation following orthopaedic
and soft tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue
surgery.

Maximum number of piercings is 42 for all presentations.
Dogs:
Musculo-skeletal disorders:
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e.
0.4 ml/10 kg body weight).
A suitable veterinary medicinal product for dogs containing 1.5 mg meloxicam per ml
oral suspension or 1 mg or 2.5 mg of meloxicam in tablet form may be used for
continuation of treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours
after administration of the injection.
Reduction of post-operative pain (over a period of 24 hours):

Revised: December 2025
MA split from NI Expiry following AN: 02234/2025
Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg
body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of
induction of anaesthesia.
Cats:
Reduction of post-operative pain:
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e.
0.06 ml/kg body weight) before surgery, for example at the time of induction of
anaesthesia.
Particular care should be taken with regard to the accuracy of dosing.
Avoid introduction of contamination during use.

Do not use in animals suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.
Refer to section 4.7.

Revised: December 2025
MA split from NI Expiry following AN: 02234/2025

Dogs and cats
Rare
(1 to 10 animals / 10,000 animals
treated):
Digestive tract disorder: loss of
appetite, vomiting, diarrhoea, blood
in faeces
Systematic disorder: depression
Renal and urinary disorders: renal
failure
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Digestive tract disorders:
haemorrhagic diarrhoea,
haematemesis, gastric ulceration
NOS. Investigations: elevated liver
enzymes.
Immune system disorders:
anaphylactoid reactions
These side effects occur generally within the first treatment week and are in most
cases transient and disappear following termination of the treatment but in very rare
cases may be serious or fatal.

Revised: December 2025
MA split from NI Expiry following AN: 02234/2025
These side effects should be treated symptomatically.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also the last section of
the package leaflet for respective contact details.

None.

Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity.
During anaesthesia, monitoring and fluid therapy should be considered as standard
practice.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Accidental self-injection may give rise to pain. People with known hypersensitivity to
non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the
veterinary medicinal product.
In view of the risk of accidental self-injection and the known adverse class-effects of
NSAIDs and other prostaglandin inhibitors on pregnancy and/or embryofoetal
development, the veterinary medicinal product should not be administered by pregnant
women or women attempting to conceive.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects. The
veterinary medicinal product must not be administered in conjunction with other
NSAIDs or gluco-corticosteroids. Concurrent administration of potential nephrotoxic
drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals)
intravenous or subcutaneous fluid therapy during anaesthesia should be taken into
consideration. When anaesthesia and NSAID are concomitantly administered, a risk
for renal function cannot be excluded.
Pre-treatment with anti-inflammatory substances may result in additional or
increased adverse effects and accordingly a treatment-free period with such
veterinary medicinal products should be observed for at least 24 hours before
commencement of treatment. The treatment-free period, however, should take into
account the pharmacological properties of the products used previously.

Keep the vial in the outer carton.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.